PensionDanmark Pensionsforsikringsaktieselskab Has $10.58 Million Stock Holdings in Zoetis Inc. $ZTS

Key Points

• PensionDanmark increased its Zoetis stake by 13.4% in the second quarter, holding 147,182 shares valued at approximately $10.58 million. Institutional investors collectively own 92.8% of the company.
• Zoetis beat quarterly EPS estimates with $1.87 per share, but revenue of $2.47 billion fell short of expectations and was essentially flat year over year. The company cut fiscal 2026 adjusted EPS guidance to $6.15–$6.25, contributing to a sharp stock decline.
• The stock traded near $72.53 after falling 6.1%, while analysts maintained an overall “Hold” rating with an average price target of $115.50. Zoetis also declared a quarterly dividend of $0.53 per share, representing a 2.9% annualized yield.

PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 13.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 147,182 shares of the company's stock after acquiring an additional 17,340 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab's holdings in Zoetis were worth $10,576,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Louisiana State Employees Retirement System acquired a new position in shares of Zoetis during the 1st quarter worth about $2,542,000. Deutsche Bank AG lifted its stake in Zoetis by 19.1% in the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company's stock valued at $699,331,000 after purchasing an additional 891,921 shares during the last quarter. Pincus Capital Management LP bought a new position in Zoetis during the fourth quarter worth about $2,109,000. Highbridge Capital Management LLC bought a new position in Zoetis during the fourth quarter worth about $7,004,000. Finally, Swedbank AB increased its position in Zoetis by 9.9% during the first quarter. Swedbank AB now owns 3,004,200 shares of the company's stock worth $355,126,000 after buying an additional 269,610 shares during the last quarter. Institutional investors own 92.80% of the company's stock.

Zoetis Trading Down 6.1%

Shares of ZTS stock opened at $72.53 on Friday. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $160.48. The company has a market capitalization of $30.41 billion, a PE ratio of 11.95, a price-to-earnings-growth ratio of 1.34 and a beta of 0.74. The firm has a 50 day moving average price of $76.66 and a two-hundred day moving average price of $100.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 70.95% and a net margin of 27.49%.The firm's quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, analysts predict that Zoetis Inc. will post 6.2 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis's dividend payout ratio (DPR) is presently 35.16%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Morgan Stanley set a $85.00 price objective on Zoetis in a research report on Friday. Citigroup decreased their target price on Zoetis from $145.00 to $112.00 and set a "buy" rating on the stock in a report on Monday, May 18th. UBS Group dropped their price target on Zoetis from $85.00 to $80.00 and set a "neutral" rating on the stock in a research note on Friday. Barclays cut their price target on Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a report on Wednesday, July 1st. Finally, Wall Street Zen cut shares of Zoetis from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $115.50.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Insider Transactions at Zoetis

In other news, Director Paul Bisaro bought 2,000 shares of the company's stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company's stock, valued at $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the firm's stock in a transaction that occurred on Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares of the company's stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source